Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: AJR Am J Roentgenol. 2015 Jan;204(1):W11–W18. doi: 10.2214/AJR.13.12412

Fig. 3.

Fig. 3

Serial CT perfusion scans in 62-year-old man with malignant fibrous histiocytoma of left thigh.

A and B, Axial contrast-enhanced CT image (A) and corresponding color blood flow map (B) show high tissue perfusion (blood flow = 160 mL/100 g/min) before start of bevacizumab therapy. Tumor size is 5.6 cm.

C and D, CT perfusion scan (C) obtained 2 weeks after start of bevacizumab therapy shows decrease in tumor perfusion (blood flow = 100 mL/100 g/min) on corresponding color blood flow map (D). Tumor size is essentially unchanged at 5.5 cm (C).

E and F, CT perfusion scan (E) obtained after treatment completion shows significant reduction in tumor perfusion (blood flow = 60 mL/100 g/min) on color blood flow map (F), whereas tumor size was unchanged at 5.6 cm.